Limes Schlosskliniken AG Stock: price and insider trades · Germany
No insider purchase over the last 90 days. The latest, by GMF Capital GmbH, was filed 18 Dec 2025.
Limes Schlosskliniken AG: what insiders have been doing
Every trade that managers of Limes Schlosskliniken AG disclose to BaFin is tracked on this page. The company sits in the Healthcare & Pharma sector. In the past year (8 November 2025 to 8 November 2026), 5 filings came from 3 insiders.
Open-market activity splits into 1 purchase totalling €70k and 4 sales totalling €8.1M; 1 insider sit on the buying side and 2 insiders on the selling side. Netting one side against the other leaves €8.1M of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. At €4.8M, the sale published on 13 April 2026 by GMF Capital GmbH is the largest of the period (2.8% of market cap).
For context, the typical company on the same exchange (median of 287 companies) published 5 filings over the same period, against 5 filings here. Looking back to 2025, when coverage begins, insiders filed 1 purchase and 4 sales.
The clock since the last published purchase (18 December 2025) now reads 325 days. Filings reach the BaFin feed a median of 3 days after the trade. Under the Market Abuse Regulation, managers have three business days to notify their trades. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by BaFin. They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- +50.6%Entry €352.00 · Close 15 Oct 2026 €530.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 200 shares@ €570.000.072% mcap100.0% of flowShareXETRAISIN DE000A0JDBC7BAFIN:40027653-0e12fa6e3ee7
- 3,000 shares@ €540.001.03% mcap20.0% of flowShareISIN DE000A0JDBC7BAFIN:40027653-d5b4d1685938
- 3,000 shares@ €530.001.05% mcap19.7% of flowShareISIN DE000A0JDBC7BAFIN:40027653-86565ba08e58
- 10,000 shares@ €480.002.80% mcap59.4% of flowShareISIN DE000A0JDBC7BAFIN:40027653-7d5342e35d55
- 197.004 shares@ €354.990.9% of flowShareFrankfurtISIN DE000A0JDBC7BAFIN:40027653Canonical exit: 17 Mar 2026 (T+90)
5 of 5 declarations
About Limes Schlosskliniken AG
Limes Schlosskliniken AG is a German listed healthcare group focused on private psychiatry and psychiatric rehabilitation, traded on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany. The company operates in a specialized niche of inpatient mental health care, offering premium, individualized treatment programs for psychological disorders. Its patient mix includes private patients, publicly insured patients with reimbursement, and patients covered by public aid. From an equity analyst perspective, the investment case rests on a rare specialist positioning, relatively high treatment intensity, and the structural undersupply of mental health capacity, balanced against staff shortages, regulatory complexity, and the execution risk of opening new clinics. ([limes-schlosskliniken.de](https://www.limes-schlosskliniken.de/app/uploads/2025/05/Annual-Report-2024-LIMES-Schlosskliniken.pdf))
The group was founded in 2005, originally under the name GMF Capital AG, and was renamed Limes Schlosskliniken AG in 2015, at the same time relocating its head office to Cologne. Limes Schlosskliniken AG serves as the central holding company of the group, overseeing strategic, financial and operational management, as well as brand development, marketing, acquisition and the development of new clinic sites. Clinic operations are run from Cologne. ([limes-schlosskliniken.de](https://www.limes-schlosskliniken.de/app/uploads/2025/05/Annual-Report-2024-LIMES-Schlosskliniken.pdf))
Read moreShow less
Limes Schlosskliniken currently operates a multi-site platform in Germany and nearby markets. Its locations include Mecklenburgische Schweiz in Teterow/Teschow, Fürstenhof in Bad Brückenau, Abtsee in the Berchtesgadener Land, and Bergisches Land in Lindlar, plus CLINICUM ALPINUM in Gaflei, Liechtenstein, and the Paracelsus Recovery Clinic in Zurich/London. The group states that it has around 400 high-quality treatment places across six clinic locations. Its treatment portfolio covers anxiety disorders, obsessive-compulsive disorders, ADHD/ADD, sleep disorders, personality disorders, chronic pain and sports psychiatry. ([limes-schlosskliniken.de](https://www.limes-schlosskliniken.de/app/uploads/2025/05/Annual-Report-2024-LIMES-Schlosskliniken.pdf))
Competitively, Limes Schlosskliniken benefits from a premium, high-service clinical model and a market environment in which demand for mental health treatment remains structurally strong while public-sector capacity is constrained by long waiting times. That said, the company is still exposed to industry-wide pressure on qualified personnel, cost inflation, and the ramp-up profile of newly opened facilities. Its model is therefore best understood as a specialized healthcare platform with operating leverage potential, but also with meaningful execution sensitivity. ([limes-schlosskliniken.de](https://www.limes-schlosskliniken.de/app/uploads/2025/05/Annual-Report-2024-LIMES-Schlosskliniken.pdf))
Recent developments have been important. The investor relations page shows the opening of Abtsee in June 2025 and Bergisches Land in July 2025, while a February 2026 trading update reported strong 2025 growth and indicated that Abtsee was already contributing positively from January 2026. The company also disclosed a directors’ dealings notification in April 2026, consistent with Germany’s MAR Article 19 transparency framework overseen by BaFin. ([limes-schlosskliniken.de](https://www.limes-schlosskliniken.de/en/investor-relations/?utm_source=openai))
